Reebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma: a multicenter case-control study

Ver

The 22/11 risk prediction model: a validated model for predicting 30-Day mortality in patients with cirrhosis and spontaneous bacterial peritonitis

Ver

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in traetment of overt hepatic encephalopathy

Ver

Spleen stiffness in patients with corrhosis in predicting esophageal varices

Ver

CT with hepatic arterioportography as a pre-treatmen examination for hepatocellular carcinoma patients: a randomized controlled trial

Ver

Effects of intravenous albumin in patients with cirrhosis and episodic encephalopathy: a randomized double-blind study

Ver

Non alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaked breath

Ver

Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B related cirrhosis

Ver

Sofosbuvir for previously untreated chronic hepatitis C infection

Ver

Faldaprevir and deleobuvir for HCV genotype 1 infection

Ver

A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis

Ver

a

Non-selective betablocker therapy decreasesintestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis

Ver

Acute exacerbation and reactivation of chronic hepatitis C infectionin cancer patients

Ver

Improvement of serum alkaline phosphatase to <1,5 upper limit of normal predicts better outcome and reduce risk of cholangiocarcinoma in primary sclerosing cholangitis

Ver

SALLA 4 gen oncofetal en carcinoma hepatocelular agresivo

Ver

High pervalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk in bacterial infections in patients with cirrhosis

Ver

Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis

Ver

Exposicion temprana a tacrolimusdespues del trasplante hepatico: relacion rechazo agudo moderado/grave y los resultados a largo plazo.

Ver

 

2016 - 2015 - 2014 - 2013 -2012 -2011 -2010 - 2009

 

 
 

 

 

Dirección: Urquiza 3100, Rosario (2000), Santa Fe, Argentina
e-mail: contactohepagastro@gmail.com
TEL: 0341-4393511

Diseño web IDEAS MED | Tabone Juan Pablo | www.ideasmed.com.ar |

Hepagastro | Dr. Federico Tanno | Todos los derechos reservados 2015.-